Prosight Management, LP Buys Cigna Corp, athenahealth Inc, Kura Oncology Inc, Sells Shire PLC, Sabra Health Care REIT Inc, DexCom Inc

• New Purchases: ATHN, KURA, NTEC, MYL, ASMB, ESPR, AQXP, KZR, CLLS,
• Added Positions: CI, PIRS, MGNX, IOVA, TLGT, ARNA, NBRV,
• Reduced Positions: SHPG, SBRA, RETA, AGN, AKAO, AVEO, CIVI, SRRA, CNC, EIGR,
• Sold Out: DXCM, QTNT, CLVS, KND, QURE, BLCM, AMPE,

For the details of Prosight Management, LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Prosight+Management%2C+LP

1. Cigna Corp (CI) - 77,400 shares, 9.65% of the total portfolio. Shares added by 140.37%
2. Macrogenics Inc (MGNX) - 618,515 shares, 9.37% of the total portfolio. Shares added by 38.99%
3. Allergan PLC (AGN) - 71,700 shares, 8.77% of the total portfolio. Shares reduced by 24.37%
4. Teligent Inc (TLGT) - 3,325,000 shares, 8.44% of the total portfolio. Shares added by 34.48%
5. Pieris Pharmaceuticals Inc (PIRS) - 1,360,000 shares, 5.06% of the total portfolio. Shares added by 141.24%

Prosight Management, LP initiated holding in athenahealth Inc. The purchase prices were between $122.47 and $161.76, with an estimated average price of $148.27. The stock is now traded at around $148.72. The impact to a portfolio due to this purchase was 4.81%. The holding were 41,193 shares as of 2018-06-30.

Prosight Management, LP initiated holding in Kura Oncology Inc. The purchase prices were between $14.8 and $18.8, with an estimated average price of $16.94. The stock is now traded at around $19.30. The impact to a portfolio due to this purchase was 3.85%. The holding were 287,887 shares as of 2018-06-30.

Prosight Management, LP initiated holding in Intec Pharma Ltd. The purchase prices were between $4.15 and $6.5, with an estimated average price of $4.96. The stock is now traded at around $4.15. The impact to a portfolio due to this purchase was 3.63%. The holding were 1,125,153 shares as of 2018-06-30.

Prosight Management, LP initiated holding in Mylan NV. The purchase prices were between $35.37 and $41.86, with an estimated average price of $39.24. The stock is now traded at around $37.82. The impact to a portfolio due to this purchase was 2.14%. The holding were 80,800 shares as of 2018-06-30.

Prosight Management, LP initiated holding in Assembly Biosciences Inc. The purchase prices were between $39.21 and $50.29, with an estimated average price of $44.09. The stock is now traded at around $35.89. The impact to a portfolio due to this purchase was 1.88%. The holding were 65,301 shares as of 2018-06-30.

Prosight Management, LP initiated holding in Esperion Therapeutics Inc. The purchase prices were between $36.2 and $76.4, with an estimated average price of $50.72. The stock is now traded at around $45.96. The impact to a portfolio due to this purchase was 1.4%. The holding were 48,800 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Cigna Corp by 140.37%. The purchase prices were between $164.65 and $180.95, with an estimated average price of $173.16. The stock is now traded at around $185.48. The impact to a portfolio due to this purchase was 5.64%. The holding were 77,400 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Pieris Pharmaceuticals Inc by 141.24%. The purchase prices were between $5.03 and $6.88, with an estimated average price of $5.95. The stock is now traded at around $5.18. The impact to a portfolio due to this purchase was 2.96%. The holding were 1,360,000 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Macrogenics Inc by 38.99%. The purchase prices were between $19.78 and $24.67, with an estimated average price of $22.52. The stock is now traded at around $19.83. The impact to a portfolio due to this purchase was 2.63%. The holding were 618,515 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Teligent Inc by 34.48%. The purchase prices were between $2.68 and $3.93, with an estimated average price of $3.15. The stock is now traded at around $4.20. The impact to a portfolio due to this purchase was 2.16%. The holding were 3,325,000 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Iovance Biotherapeutics Inc by 109.63%. The purchase prices were between $12.45 and $16.95, with an estimated average price of $14.62. The stock is now traded at around $16.30. The impact to a portfolio due to this purchase was 2.16%. The holding were 439,900 shares as of 2018-06-30.

Prosight Management, LP added to a holding in Nabriva Therapeutics PLC by 73.64%. The purchase prices were between $3.39 and $5.43, with an estimated average price of $4.58. The stock is now traded at around $2.54. The impact to a portfolio due to this purchase was 0.46%. The holding were 421,414 shares as of 2018-06-30.

Prosight Management, LP sold out a holding in DexCom Inc. The sale prices were between $70.15 and $100.89, with an estimated average price of $84.75.

Prosight Management, LP sold out a holding in Quotient Ltd. The sale prices were between $3.93 and $8.93, with an estimated average price of $5.83.

Prosight Management, LP sold out a holding in Clovis Oncology Inc. The sale prices were between $42.06 and $62.4, with an estimated average price of $48.66.

Prosight Management, LP sold out a holding in Kindred Healthcare Inc. The sale prices were between $8.85 and $9.05, with an estimated average price of $8.96.

Prosight Management, LP sold out a holding in uniQure NV. The sale prices were between $21.96 and $39.94, with an estimated average price of $31.97.

Prosight Management, LP sold out a holding in Bellicum Pharmaceuticals Inc. The sale prices were between $6.36 and $9.93, with an estimated average price of $7.79.